| 摘要 |
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, namely to oncology, and can be used for treating a disease, associated with target cells, expressing CD138. For this purpose to a patient in need introduced is an effective quality of an immunoconjugate, which contains at least one targeting antibody, for which CD138-expressing cells represent the target, and at least one effector molecule, where the said targeting antibody if functionally bound with the said effector molecule with the formation of the said immunoconjugate, where at least one targeting antibody contains a heavy chain, which is identical to sequence SEQ ID NO: 1, by at least 70%, and a light chain, which is identical to sequence SEQ ID NO: 2 by at least 70%, and where the said patient has a resistance phenotype. The group of inventions also relates to an anticancer combination and an anticancer set, containing the said immunoconjugate.EFFECT: application of the immunoconjugate in a combination with a cyctotoxic preparation results in a synergic anticancer effect.61 cl, 3 ex, 30 dwg, 19 tbl |
